Merck Manual

Please confirm that you are a health care professional

honeypot link

TNF Receptor–Associated Periodic Syndrome (TRAPS)

(Familial Hibernian Fever)

By

Apostolos Kontzias

, MD, Stony Brook University School of Medicine

Last full review/revision Jan 2022| Content last modified Jan 2022
Click here for Patient Education
Topic Resources

Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis is clinical and by genetic testing. Treatment is with corticosteroids, etanercept, anakinra, and canakinumab.

Tumor necrosis factor (TNF) receptor–associated periodic syndrome (TRAPS) was originally described in a family of Irish and Scottish pedigree but has been reported in many different ethnic groups. It results from

  • Mutations in the gene coding TNF receptor 1 (TNFR1)

The mutation leads to aberrant inflammation due to accumulation of misfolded TNFR1 in the endoplasmic reticulum, which activates the unfolded protein response. This response is an attempt to correct the abnormal proteins, but it generates reactive oxygen species that trigger inflammation ( 1 General reference Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more ).

General reference

Symptoms and Signs

The most distinctive features of an attack are fever and migratory myalgia and swelling in the extremities. The overlying skin is red and tender.

Other symptoms of TRAPS may include headache, abdominal pain, diarrhea or constipation, nausea, painful conjunctivitis, periorbital edema, joint pain, rash, and testicular pain. Males are prone to developing inguinal hernias.

Autoinflammatory periodic fever disorders

Autoinflammatory periodic fever disorders

CAPS = cryopyrin-associated periodic syndromes; FMF = familial Mediterranean fever; NOMID = neonatal-onset multisystem inflammatory disease; PFAPA = periodic fevers with aphthous stomatitis, pharyngitis, and adenitis; TRAPS = tumor necrosis factor receptor–associated periodic syndrome.

Adapted from Sag E, Bilginer Y, Ozen S: Autoinflammatory diseases with periodic fevers. Curr Rheumatol Rep 19(7):41, 2017. doi: 10.1007/s11926-017-0670-8

Symptoms and signs reference

  • 1. Lachmann HJ, Papa R, Gerhold K, et al: The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: A series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 73(12):2160–2167, 2014. doi: 10.1136/annrheumdis-2013-204184

Diagnosis

  • Clinical evaluation

  • Genetic testing

Diagnosis of TRAPS is based on history, examination, and genetic testing.

Proposed diagnostic criteria include the presence of a positive family history, long-lasting fever episodes, periorbital edema, migratory rash, and myalgia and the absence of vomiting and aphthous ulcers. These criteria have a sensitivity of 59% and a specificity of 84% ( 1 Diagnosis reference Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more ).

Nonspecific findings include neutrophilia, elevated acute-phase reactants, and polyclonal gammopathy during attacks. Patients should be screened regularly for proteinuria.

Diagnosis reference

  • 1. Federici S, Sormani MP, Ozen S, et al: Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 74(5):799–805, 2015. doi: 10.1136/annrheumdis-2014-206580

Treatment

  • Corticosteroids

  • Anakinra and canakinumab

Short-term corticosteroids (prednisone at least 20 mg orally once a day), with or without nonsteroidal anti-inflammatory drugs, are effective for terminating inflammatory attacks. The dosage may need to be increased over time and this therapy may, over time, lead to more prolonged flare-ups.

Other options include anakinra 100 mg subcutaneously once a day ( 1 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more , 2 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more ) and canakinumab 150 mg subcutaneously every 4 weeks ( 3 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more , 4 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more ). Etanercept has proved to be only partially effective ( 5 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more , 6 Treatment references Tumor necrosis factor receptor–associated periodic syndrome is an autosomal dominant disorder causing recurrent fever and painful, migratory myalgias with tender overlying erythema. Diagnosis... read more ).

Treatment references

  • 1. ter Haar NM, Oswald M, Jeyaratnam J, et al: Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636–1644, 2015. doi: 10.1136/annrheumdis-2015-207546

  • 2. Gattorno M, Pelagatti MA, Meini A, et al: Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520, 2008. doi: 10.1002/art.23475

  • 3. Gattorno M, Obici L, Cattalini M, et al: Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study. Ann Rheum Dis 76(1):173–178, 2016. doi: 10.1136/annrheumdis-2015-209031

  • 4. De Benedetti F, Gattorno M, Anton J, et al: Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919, 2018. doi: 10.1056/NEJMoa1706314

  • 5. Drewe E, McDermott EM, Powell PT, et al: Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients. Rheumatology 42:235–239, 2003. doi: 10.1093/rheumatology/keg070

  • 6. Quillinan N, Mannion G, Mohammad A, et al: Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70(9):1692–1693, 2011. doi: 10.1136/ard.2010.144279

Drugs Mentioned In This Article

Drug Name Select Trade
ENBREL
KINERET
ILARIS
RAYOS
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
quiz link

Test your knowledge

Take a Quiz! 
iOS ANDROID
iOS ANDROID
iOS ANDROID
TOP